023910 — DaehanPharmaceutical Share Price
Last trade - 00:00- KR₩166bn
- KR₩62bn
- KR₩196bn
- 98
- 87
- 70
- 99
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 5.38 | ||
| PEG Ratio (f) | 0.87 | ||
| EPS Growth (f) | 6.6% | ||
| Dividend Yield (f) | 2.5% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | 9.47 | ||
| Price to Sales | 0.85 | ||
| EV to EBITDA | 1.4 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.12% | ||
| Return on Equity | 12.01% | ||
| Operating Margin | 18.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 168,761.72 | 166,079.88 | 171,462.79 | 184,267.55 | 195,911.46 | 212,850 | 232,600 | 4.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -2.25 | -17.25 | -2.37 | +10.41 | +15.72 | +5.98 | +7.82 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DAIHAN PHARMACEUTICAL CO.,LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceuticals. The Company provides infusions, including basic infusions, nutritional infusions and infusions for special uses; injections for anesthetics, vitamin-minerals, autonomic nerve systems, hypnotic-sedatives, antispasmodics, antidotes, hormones, analgesics, respiratory and others; contrast media, such as drugs for computed tomography (CT) uses and magnetic resonance imaging (MRI) uses, and other drugs, such as drugs for irrigations, ointments, inhalants, as well as quasi-drugs such as hand gels, lens clean solutions and others.
Directors
- Dong Yil Lee PRE (59)
- Yun Wu Lee CEO (69)
- Myeong Heok Yim OTH (68)
- Bok Su Yum DRC (71)
- Mun Seon Lee NID (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 11th, 1963
- Public Since
- November 23rd, 1994
- No. of Shareholders
- 8,545
- No. of Employees
- 708
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 5,880,000
- Address
- 3, Seonyu-ro 45-gil, Yeongdeungpo-gu, SEOUL, 07209
- Web
- https://www.daihan.com/main/main.php
- Phone
- +82 226783911
- Auditors
- Sahmduk Accounting Corp.
Upcoming Events for 023910
Similar to 023910
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
Ahn-Gook Pharmaceutical Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 01:06 UTC, shares in DaehanPharmaceutical are trading at KR₩28,300. This share price information is delayed by 15 minutes.
Shares in DaehanPharmaceutical last closed at KR₩28,300 and the price had moved by +1.61% over the past 365 days. In terms of relative price strength the DaehanPharmaceutical share price has outperformed the FTSE Developed Asia Pacific Index by +1.7% over the past year.
The overall consensus recommendation for DaehanPharmaceutical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The DaehanPharmaceutical dividend yield is 2.65% based on the trailing twelve month period.
Last year, DaehanPharmaceutical paid a total dividend of KR₩750, and it currently has a trailing dividend yield of 2.65%. We do not have any data on when DaehanPharmaceutical is to next pay dividends.
We do not have data on when DaehanPharmaceutical is to next pay dividends. The historic dividend yield on DaehanPharmaceutical shares is currently 2.65%.
To buy shares in DaehanPharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩28,300, shares in DaehanPharmaceutical had a market capitalisation of KR₩166bn.
Here are the trading details for DaehanPharmaceutical:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 023910
Based on an overall assessment of its quality, value and momentum DaehanPharmaceutical is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in DaehanPharmaceutical is KR₩40,000. That is 41.34% above the last closing price of KR₩28,300.
Analysts covering DaehanPharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of KR₩5,132 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DaehanPharmaceutical. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -5.06%.
As of the last closing price of KR₩28,300, shares in DaehanPharmaceutical were trading +1.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The DaehanPharmaceutical PE ratio based on its reported earnings over the past 12 months is 5.38. The shares last closed at KR₩28,300.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
DaehanPharmaceutical's management team is headed by:
- Dong Yil Lee - PRE
- Yun Wu Lee - CEO
- Myeong Heok Yim - OTH
- Bok Su Yum - DRC
- Mun Seon Lee - NID